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OBJECTIVES: To explore the major determinants associated with treatment switch
in CHB treated patients from a cohort across 5 EU countries. METHODS: Multivar-
iate Cox proportional hazard regression model was used to analyze determinants
of treatment switch by a backward selection. Data analyzed were derived from an
observational cohort study, consisting of diagnosed adult CHB patients managed in
outpatient clinics, prospectively enrolled from March-2008 to October-2009, in
France, Germany, Poland, Romania and Turkey. Patients with HIV and/or HCV
co-infection and hepatocellular-carcinoma or liver failure at baseline were ex-
cluded. Factors considered candidates to enter the multivariate model (with uni-
variate test at p-value0.20) were: country, ALT level before switch, VL level before
switch, liver biopsy test performed, Hepatitis B e-antigen status, CHB status, age
and agent received before switch. The statistical criteria for exclusion at each step
of the model building process is p-value0.05. Results are presented as hazard
ratio(HR), [95% confidence interval] and p-value. RESULTS: Data were collected for
1267 patients followed for up to 2 years with a median (months) ranging from 12.5
(Poland) to 14.5 (Romania). A total of 567 patients received a treatment at baseline
and were included in the model to analyze the determinants of treatment switch.
Time on last treatment before switch was 1.9 years (median). There is a higher
probability to treatment switch in France (5.19;[1.76-15.24];p.0027), Germany
(4.80;[1.60-14.39];p.0050), and Poland (4.42;[1.41-13.83];p.0106) compared to Tur-
key. No statistically difference in Romania. There is a higher probability to treat-
ment switch when VL2000IU/ml (4.35;[2.52-7.52];p.0001) compared to Undetect-
able and VL2000IU/ml. Analysis of interaction showed that VL when associated
with a performed liver biopsy test increase probability of switch. CONCLUSIONS:
This observational cohort identified VL level as a major clinical outcome driving the
treatment switch decision in CHB treated patients. Results were statistically differ-
ent across countries, possibly due to different health care policies.
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OBJECTIVES: To explore the perceptions’ of hospital pharmacists towards drug
management and reasons underlying stock outs of anti-malarial drugs in Pakistan.
METHODS:A qualitative study was designed to explore the perceptions’ of hospital
pharmacists regarding drug management and irrational use of anti-malarial drugs
in two major cities of Pakistan, namely, Islamabad (national capital) and Rawal-
pindi (twin city). Semi-structured interviews were conducted using in-depth inter-
view guides to collect data. Sixteen interviews with hospital pharmacists working
at different public and private hospitals in Islamabad and Rawalpindi were con-
ducted at a place and time convenient for the respondents. Interviews, were audio-
taped and transcribed verbatim, were evaluated by thematic content analysis and
by other authors’ analysis. RESULTS: The interviews with hospital pharmacists
focused on three major components i.e. drug management, contributing factors in
stock-outs, role of hospital pharmacist and suggestions for improvements. The-
matic content analysis of these components yielded further themes.1,2) Preva-
lence and current scenario of malaria treatment practices 3) Major contributing
factors towards irrational treatment practices for malaria 4,5,6) Role of health care
system and hospital pharmacist and influencing factor effective drug management
and treatment practices 5 7) Collaborative working of doctors and pharmacists 8)
Role of Malaria Control Program 9) Management of anti-malarial drugs in the
health care facilities 9,10,11) Current scenario, contributing factors and strategies
to improve in anti-malarial drugs stock outs. CONCLUSIONS: The current study
showed that all the respondents in the two cities agreed that hospital pharmacist
has failed to play an effective role in efficient management of anti-malarial drugs
stock-outs.
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OBJECTIVES: Cross-country regressions have been used to assess the relationship
between malaria and economic growth. However, more detailed estimates of the
broad economic impact of malaria interventions targeting children i.e. impact at
household level and per region are relevant to donors and policymakers. Therefore,
we simulate the impact of reducing malaria morbidity and mortality on the Gha-
naian economy utilising a micro-based approach. METHODS: A multi-sector,
multi-agent, dynamic-computable-general-equilibrium (DCGE) model is devel-
oped and linked with health models that estimate: (1) regional demographics with
cohort-component projections for fertility, mortality, migration, and urbanization;
(2) labour indices for production and productivity of parents with sick children or
adults affected by malaria during childhood. We leave out any additional effects
(tourism spending, foreign investment, etc.). The model is calibrated to Ghana,
with households disaggregated by five epidemiological malaria regions, urban-
rural divide, and income level quintiles. Hypothetical intervention scenarios are
simulated reducing malaria prevalence by 50%, for children 5years with varying
degrees of coverage. RESULTS: Average yearly GDP would rise by 0.8% above base-
line. Due to regional heterogeneity in labour resources, preferences, and malaria
prevalence, the income-benefit per child covered by the intervention ranges be-
tween $1-$14, $5-$50 and $66-$540 (2007 US Prices) with national averages of $8, $34
and $300 at y1, y15 and y25 respectively. We also find that malaria prevention
contributes more to income and consumption in high prevalence regions, and
slows down the rise in income inequalities under the limitation that the model
does not include the informal sector. CONCLUSIONS: Investing in malaria preven-
tion in children can have an observable impact on the wider economy and may
contribute to poverty reduction. We contribute with: (1) a public economics ap-
proach to analysing malaria impact on economic growth (2) viewing effects at
national, regional, and income level dimension; (3) a suitable method for other
diseases.
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OBJECTIVES: In Europe, the time between regulatory approval and population ac-
cess for vaccines exceeds that for other pharmaceutical products. This difference
has been shown to be linked to the recommendation phase, where NITAGs assess
new vaccines before implementation into vaccination programmes and coverage
by health insurance. The objective of this research was to study and compare
NITAGs’ policies and decision-making processes in 9 European and 4 non-Euro-
pean countries. METHODS: We developed a standardized extraction grid with 25
items covering: overall NITAG organization, existence of terms of reference, mem-
ber’s appointments and profiles, meeting organization, decision analytic frame-
work, processes and communication. The research was conducted by review of the
NITAG or mother agency websites, and a literature review and direct contact with
a NITAG member by email, and when possible by telephone interview. RESULTS:
Information was rarely available online or through public sources. Direct contact
was necessary to obtain information for most countries. Only 2 EU countries (and
the 4 non-EU countries) have formal terms of reference. In most cases defined
missions do not fit to actual ones. Numbers (8 to 48) and backgrounds of experts
varied dramatically. 69% of NITAGs have analytical frameworks, 8% have publicly-
opened meetings, 15% publish meeting agendas, 31% publish minutes and 85%
publish recommendations. The vast majority have no defined timelines for
decision-making. CONCLUSIONS: Wide variability in organization processes and
communication is seen between NITAGs. In Europe, NITAGs with few terms of
references and no communication of meeting agendas or minutes suggests the
lack of a structured and transparent decision-making process. There is an obvious
need for improving the vaccine decision-making process. Some interesting initia-
tives from individual NITAGs could be taken as examples and assembled together
for a benchmark exercise. Recommendations for best practices in vaccine decision
making are critical to public health and will be discussed.
PIN84
TRENDS IN PREVALENCE OF ANTIBACTERIAL DRUG USE AMONG DUTCH
CHILDREN FROM 2005 UNTIL 2010
Joosten SGL1, Houweling LMA2, Penning FJA2
1Utrecht University, Utrecht, The Netherlands, 2PHARMO Institute for Drug Outcomes Research,
Utrecht, The Netherlands
OBJECTIVES: Systemic antibacterials are frequently used by children. We assessed
trends in prevalence of antibacterial drug use among Dutch children from 2005
until 2010. METHODS: The PHARMO Record Linkage System, containing amongst
others outpatient pharmacy dispensing data of 3.2 million inhabitants in the
Netherlands, was used for this study. For every year in the study period 2005-2010,
the number of children aged 0-18 years with any dispensing of systemic antibac-
terials and per subtype was counted and extrapolated to the Netherlands, stan-
dardized for age and gender. Prevalence of use was reported per 10,000 children
and was stratified by calendar year, age group (2 years: infants and toddlers, 2-11
years: children, 12-18 years: adolescents) and gender. RESULTS: The prevalence of
antibacterial drug use decreased 1.1-fold among infants and toddlers (from 2,231 to
2,041 per 10,000), decreased 1.3-fold among children (from 1,979 to 1,564 per
10,000), but remained constant among adolescents (1,193 per 10,000). A decrease of
use was mainly observed in the most prevalent types; penicillins with extended
spectrum and macrolides. However, also trimethoprim and derivatives were less
frequently used, especially among female adolescents (from 163 to 92 per 10,000).
Prevalence of beta-lactamase resistant penicillins increased from 2 to 29 per 10,000
among infants and toddlers and from 44 to 77 per 10,000 among children. An
increase in nitrofuran derivatives was observed among female children (from 38 to
100 per 10,000) and female adolescents (from 267 to 413 per 10,000).CONCLUSIONS:
This study provides an extensive overview of trends in antibacterial drug use
among children in the Netherlands. An overall decrease of use was observed, while
an increase was observed for nitrofuran derivatives and beta-lactamase resistant
penicillins.
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